MSD has re-entered the RNA field by acquiring German biotech, Rigontech who harnesses RNA interference in order to make the immune system attack cancer cells.

Rigontech focuses on immune-oncology applications of RNA, reports Labiotech. MSD will pay a total of €115m upfront, a figure that could in fact increase up to €464m if its assets meet specific milestones.

MSD has been absent from the RNA field ever since it sold Sirna Therapeutics three years ago for almost a tenth of the acquisition price. But with its new return, it is certainly set to make some movements. 

More on these topics